Abivax to Participate in Upcoming Investor Conferences
Abivax has announced its scheduled participation in several investor conferences taking place this autumn.
Stocks · News reference
These Analysts Slash Their Forecasts On Abivax Following H1 Results
Abivax missed EPS estimates but beat sales in H1; shares dipped. Wedbush and Truist cut price targets to $118 and $151.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Abivax shares are trading higher after Guggenheim reiterated its Buy rating on the stock and maintained a $175 price target.
Guggenheim Reiterates Buy on Abivax, Maintains $175 Price Target
Guggenheim analyst Yatin Suneja reiterates Abivax (NASDAQ:ABVX) with a Buy and maintains $175 price target.
Abivax To Present Seven Scientific Abstracts On Obefazimod, Lead Drug Candidate For Treatment Of Active Ulcerative Colitis At UEG Week 2026 Meeting
BTIG Reiterates Buy on Abivax, Maintains $175 Price Target
BTIG analyst Julian Harrison reiterates Abivax (NASDAQ:ABVX) with a Buy and maintains $175 price target.
Truist Securities Maintains Buy on Abivax, Lowers Price Target to $151
Truist Securities analyst Gregory Renza maintains Abivax (NASDAQ:ABVX) with a Buy and lowers the price target from $155 to $151.